Home

Insights

Dividend

Suven Pharmaceuticals Ltd dividend

Suven Pharmaceuticals Ltd dividend

download
stocks purchased

₹ 4.3 Cr

Volume transacted

stocks purchased

50.6 K

stocks traded

Last Updated time: 13 Jul 15:07 PM

Image

Suven Pharmaceuticals Ltd

NSE: SUVENPHAR

DPS

6

Last updated : FY 2023

Key Highlights

    The Dividend per Share of Suven Pharmaceuticals Ltd is ₹ 6 as of 2023 .a1#The Dividend Payout of Suven Pharmaceuticals Ltd changed from 23.57 % on March 2019 to 35.31 % on March 2023 . This represents a CAGR of 10.63% over 4 years. a1#The Latest Trading Price of Suven Pharmaceuticals Ltd is ₹ 848.75 as of 12 Jul 15:30 .a1#The Market Cap of Suven Pharmaceuticals Ltd changed from ₹ 2564 crore on March 2019 to ₹ 12033 crore on March 2023 . This represents a CAGR of 47.18% over 4 years. a1#The Revenue of Suven Pharmaceuticals Ltd changed from ₹ 349.83 crore to ₹ 269.98 crore over 8 quarters. This represents a CAGR of -12.15% a1#The EBITDA of Suven Pharmaceuticals Ltd changed from ₹ 161.92 crore to ₹ 90.4 crore over 8 quarters. This represents a CAGR of -25.28% a1#The Net Pr of Suven Pharmaceuticals Ltd changed from ₹ 107.54 crore to ₹ 53.37 crore over 8 quarters. This represents a CAGR of -29.55% a1#

Open Demat Account

Lead form image

Enter your mobile no. to continue

+91

*By signing up you agree to our terms & conditions

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

Share Price Vs Dividend Yield

swot
swot

Company Fundamentals For Suven Pharmaceuticals Ltd

Market Cap

21,606 Cr

EPS

11.8

P/E Ratio (TTM) *

71.9

P/B Ratio (TTM) *

10.5

DTE *

0.0

ROE *

14.6

ROCE *

19.5

Dividend Yield *

1.27

DPS *

6

Dividend Payout *

35.31

Ann.Dividend % *

600

* All values are consolidated

Last Updated time: 13 Jul 15:07 PM

* All values are consolidated

Last Updated time: 13 Jul 15:07 PM

×

Historical Dividend Payout of Suven Pharmaceuticals Ltd

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Historical Dividend Payout of Suven Pharmaceuticals Ltd

Period
Mar '190
Mar '2024
Mar '2117
Mar '2223
Mar '2335

* All values are a in %

Dividend per Share (DPS) Over Time

×

DIVIDENDYIELD

Dividend Yield is a financial ratio that shows the annual dividend income relative to the market price of a share. It is calculated by dividing the dividend per share by the current market price per share, expressed as a percentage.

Dividend Yield Comparison With Top Peers

1M

1Y

3Y

5Y

* All values are in %

Net Profit Vs Dividend Per Share

Image

Suven Pharmaceuticals Ltd

NSE: SUVENPHAR

PRICE

848.75

-6.90 (-0.81%)

stock direction

Last updated : 12 Jul 15:30

SWOT Analysis Of Suven Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Suven Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Overview of Dividend

Types of Dividend


Special Dividend

A dividend is paid on common stock when a company has accumulated substantial profits over years, often seen as excess cash that doesn't need immediate use.


Preferred Dividend

A quarterly dividend is paid to preferred stock owners, typically accumulating a fixed amount, and is earned on shares that function more like bonds.


Interim Dividend

Companies declare interim dividends before final full-year accounts are prepared, specifically in India, during the financial year from April to March of the following year.


Final Dividend

A final dividend is issued after the year's accounts have been compiled. Aside from this, the following list highlights the most prevalent sorts of dividends:


×

Historical Market Cap of Suven Pharmaceuticals Ltd

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Historical Market Cap of Suven Pharmaceuticals Ltd

Period
Mar '190
Mar '202564
Mar '2112611
Mar '2215731
Mar '2312033

* All values are a in crore

×

Historical Revenue of Suven Pharmaceuticals Ltd

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Historical Revenue of Suven Pharmaceuticals Ltd

Period
Jun '22350
Sep '22289
Dec '22367
Mar '23381
Jun '23358
Sep '23251
Dec '23234
Mar '24270

* All values are a in crore

×

Historical EBITDA of Suven Pharmaceuticals Ltd

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

Historical EBITDA of Suven Pharmaceuticals Ltd

Period
Jun '22162
Sep '22111
Dec '22160
Mar '23183
Jun '23178
Sep '23118
Dec '2380
Mar '2490

* All values are a in crore

×

Historical Net Profit of Suven Pharmaceuticals Ltd

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Historical Net Profit of Suven Pharmaceuticals Ltd

Period
Jun '22108
Sep '2272
Dec '22108
Mar '23124
Jun '23121
Sep '2380
Dec '2347
Mar '2453

* All values are a in crore

About Suven Pharmaceuticals Ltd

About Suven Pharmaceuticals Ltd

    Suven Pharmaceuticals Limited (SPL) is a bio-pharmaceutical company, incorporated on 6th November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. The Company is a CDMO that supports global life sciences industry and fine chemical majors in their NCE development endeavors. Its services include custom synthesis, process R&D, scale-up and contract manufacturing of intermediates, APIs and formulations. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry. During the year 2019-20, Suven Life Sciences Ltd. (SLSL) has transferred the CRAMS business undertaking to the Company in accordance with the Scheme of Arrangement (Demerger) approved by the Hon'ble NCLT, Hyderabad Bench now integrated with Contract Development and Manufacturing Operations (CDMO) business model of the Company. In terms of the sanctioned Scheme, the Company issued and allotted 1 (One) fully paid up equity share of face value of Re 1/- (Rupee One only) each of SPL for every 1 (One) fully paid up equity share of face value of Re 1/- (Rupee One only) each held by each shareholder in the Demerged Company (SLSL) as on the Record Date (i.e., 22nd January, 2020), thereby resulted in a mirror shareholding of SLSL in the Company. The equity shares of the Company were listed to trade w.e.f. 09th March, 2020. The Board of Directors in its meeting held on August 17, 2020 considered, approved and recommended an issue of bonus shares in the proportion of (1:1) one new equity share of the Company of Re 1 each for every one existing equity share of the Company of Re 1 each. The company has a massive Rs 320-crore capex plan. Suven has invested Rs 120 crore in 2019-20. The balance is to be invested in 2020-21. During the year 2019-20, the Company invested USD35 million in Rising Pharma Holdings, Inc., USA through its wholly owned subsidiary, Suven Pharma, Inc., USA. Suven Pharma, Inc., in USA was originally formed by Suven Life Sciences Ltd while pursuing various business opportunities in CRAMS business undertaking during the demerger transition period now integrated with CDMO business of the Company, as per the decisions taken by the Board of the Company and of the Demerged Company i.e., Suven Life Sciences Ltd, in accordance with the enabling provisions of Scheme of Arrangement as sanctioned by Hon'ble NCLT Hyderabad Bench. As a result, Suven Pharma, Inc., in USA has become wholly owned subsidiary of the company during the FY 2019-2020. As on 31 March 2020,the company has one subsidiary and one associate company under its roof. The company filed 11 ANDAs as on March 31, 2020 and three of those secured the green light from the regulator. The Board has allotted the Bonus shares at 1:1 ratio in its Board Meeting held on 29 September 2020. Accordingly the number of shares increased from 12,72,82,478 to 25,45,64,956.. In 2022, the Company filed 17 ANDAs of which 9 had received approvals and 8 products were launched up to March, 2022. During year 2022, Company acquired 100% stake in Casper Pharma Private Limited, a Hyderabad based SEZ unit and Casper Pharma became a Wholly Owned Subsidiary of the company.

Suven Pharmaceuticals Ltd News Hub

News

Suven Pharma soars after signing deal to acquire oligo drugs maker Sapala Organics

Sapala Organics is a Hyderabad-based CDMO focused on oligo drugs and nucleic acid building...

Read more

14 Jun 202412:21

News

Board of Suven Pharmaceuticals approves investment in a renewable entity

The Board of Suven Pharmaceuticals at its meeting held on 30 May 2024 has approved the pro...

Read more

31 May 202410:47

News

Suven Pharmaceuticals postpones board meeting

Suven Pharmaceuticals has postponed the meeting of the Board of Directors which was schedu...

Read more

22 May 202414:26

News

Suven Pharmaceuticals schedules board meeting

Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 27 M...

Read more

20 May 202417:36

News

Suven Pharmaceuticals receives revision in credit ratings

Suven Pharmaceuticals announced that CRISIL has assigned the rating 'CRISIL A+/ Watch Posi...

Read more

12 Mar 202414:03

News

Suven Pharma climbs 15% in two days on merger plan

On 29 February 2024, Suven Pharmaceuticals and Cohance Lifesciences announced a proposed s...

Read more

02 Mar 202412:25

FAQs for dividends of Suven Pharmaceuticals Ltd

What is the current market price of Suven Pharmaceuticals Ltd Ltd as of July 13, 2024?

The current market price of Suven Pharmaceuticals Ltd Ltd stands at 848.8 per share.

What dividend did Suven Pharmaceuticals Ltd declare in the last fiscal year?

In the last fiscal year, Suven Pharmaceuticals Ltd declared a dividend totaling ₹0.0.

What is the most recent dividend declared by Suven Pharmaceuticals Ltd?

Suven Pharmaceuticals Ltd recently declared a dividend of 0.0 in the latest quarter

How many times has Suven Pharmaceuticals Ltd declared dividends in the current fiscal year

Suven Pharmaceuticals Ltd has declared dividends 4 times totaling ₹0 in the current fiscal year (FY2023-2024).

How many times did Suven Pharmaceuticals Ltd declare dividends in the previous fiscal year?

In the previous fiscal year (FY2022-2023), Suven Pharmaceuticals Ltd declared dividends 4 times totaling ₹6.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199